Holen Sie sich die Stockscreener-App
6.525
3.05%
-0.205
Schlusskurs vom Vortag:
$6.73
Offen:
$6.8
24-Stunden-Volumen:
56,050
Relative Volume:
0.84
Marktkapitalisierung:
$109.13M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.88M
KGV:
-6.6582
EPS:
-0.98
Netto-Cashflow:
$-10.29M
1W Leistung:
+6.10%
1M Leistung:
-2.17%
6M Leistung:
-3.05%
1J Leistung:
+11.92%
1-Tages-Spanne:
$6.41
$6.80
1-Wochen-Bereich:
$6.05
$7.30
52-Wochen-Spanne:
$4.65
$10.24
Coya Therapeutics Inc Stock (COYA) Company Profile
Firmenname
Coya Therapeutics Inc
Sektor
Branche
Telefon
650.739.3939
Adresse
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
Vergleichen Sie COYA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COYA
Coya Therapeutics Inc
|
6.525 | 108.71M | 0 | -14.88M | -10.29M | -0.98 |
|
VRTX
Vertex Pharmaceuticals Inc
|
388.43 | 99.72B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
587.79 | 60.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.31 | 58.15B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.46 | 41.45B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
299.67 | 36.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-09 | Eingeleitet | Lake Street | Buy |
| 2024-12-04 | Eingeleitet | D. Boral Capital | Buy |
Coya Therapeutics Inc Aktie (COYA) Neueste Nachrichten
Coya Therapeutics, Inc. (COYA) Now Trades Above Golden Cross: Time to Buy? - Zacks Investment Research
Applying Elliott Wave Theory to Coya Therapeutics Inc.Portfolio Value Summary & Risk Managed Investment Signals - Newser
Tools to monitor Coya Therapeutics Inc. recovery probability2025 Earnings Impact & Community Verified Swing Trade Signals - Newser
Trend Dashboard Flags Coya Therapeutics Inc. As Potential Swing Trade getLinesFromResByArray error: size == 0 - kangso.co.kr
Will Coya Therapeutics Inc. stock recover after recent drop2025 Valuation Update & Growth-Oriented Investment Plans - Newser
Analyzing net buyer seller activity in Coya Therapeutics Inc.Share Buyback & AI Powered Market Entry Ideas - Newser
What Fibonacci levels say about Coya Therapeutics Inc. reboundGap Down & Verified Momentum Stock Watchlist - Newser
Can Coya Therapeutics Inc. hit a new high this month2025 Historical Comparison & Accurate Intraday Trade Tips - Newser
Coya Therapeutics shares fall 8.24% intraday despite FDA acceptance of IND application for COYA 302. - AInvest
What's Going On With Coya Therapeutics Stock? - Benzinga
Coya Therapeutics stock soars after FDA accepts IND for ALS treatment - Investing.com Australia
Coya Therapeutics' FDA-Accepted IND for COYA 302: A Catalyst for ALS Therapy Innovation and Investment Potential - AInvest
Coya Therapeutics announces FDA acceptance of investigational new drug (IND) application - MarketScreener
Coya Therapeutics and the FDA IND Acceptance: A Pivotal Step in the Race for ALS Treatment Innovation - AInvest
Coya Therapeutics Receives FDA Approval for COYA 302 ALS Treatment Trial - AInvest
Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) - PR Newswire
Positive Outlook for Coya Therapeutics Amid Promising Developments and Financial Stability - TipRanks
Using Python tools to backtest Coya Therapeutics Inc. strategies2025 Retail Activity & Low Drawdown Trading Techniques - Newser
Can swing trading help recover from Coya Therapeutics Inc. lossesPortfolio Update Summary & Free Risk Controlled Daily Trade Plans - Newser
How much upside does Coya Therapeutics Inc. haveMarket Risk Report & Real-Time Chart Pattern Alerts - theviewers.co.kr
Is Coya Therapeutics Inc. part of any ETFAnalyst Downgrade & Precise Entry and Exit Recommendations - theviewers.co.kr
Is Coya Therapeutics Inc. in a long term uptrendJuly 2025 Drop Watch & Consistent Return Strategy Ideas - sundaytimes.kr
Published on: 2025-08-20 06:04:05 - Newser
Is Coya Therapeutics Inc. trending in predictive chart modelsPortfolio Growth Summary & Real-Time Stock Price Movement Reports - Newser
Understanding Coya Therapeutics Inc.’s price movementWeekly Gains Report & Weekly Watchlist for Hot Stocks - Newser
Is Coya Therapeutics Inc. stock ready for a breakoutJuly 2025 Volume & High Accuracy Swing Entry Alerts - Newser
How Resilient Is Coya Therapeutics Inc. Stock During Economic Downturns2025 Macro Impact & Daily Entry Point Trade Alerts - Newser
Applying Wyckoff theory to Coya Therapeutics Inc. stockWeekly Market Summary & Daily Growth Stock Tips - Newser
How volatile is Coya Therapeutics Inc. stockPortfolio Growth Summary & Weekly High Conviction Ideas - newsyoung.net
Why Coya Therapeutics Inc. stock attracts strong analyst attentionRate Hike & Daily Technical Stock Forecast Reports - 선데이타임즈
Published on: 2025-08-16 02:30:48 - newsyoung.net
Regulatory Risk and Reward: Navigating FDA Delays in the ALS Therapeutics Landscape - AInvest
Coya Therapeutics reports Q2 EPS (36c), consensus (43c) - MSN
Coya Therapeutics 2025 Q2 Earnings Sharp Loss Widens, Revenue Collapses - AInvest
Coya Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Coya Therapeutics’ (COYA) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Coya Therapeutics, Inc. (COYA) Reports Q2 Loss, Lags Revenue Estimates - MSN
Coya Therapeutics shares rise 2.46% after-hours after announcing participation in H.C. Wainwright 3rd Annual BioConnect Conference. - AInvest
Coya Therapeutics Inc. recovery potential after sell offStock Surge & Community Consensus Stock Picks - Newser
Coya Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update - BioSpace
Coya Therapeutics Reports Increased Losses Amid Development Focus - TipRanks
Coya Therapeutics' $75M Mixed Shelf: Fueling Neuroinflammation Breakthroughs in ALS, Alzheimer's, and Dementia - AInvest
Coya Therapeutics Files $75 Million Mixed Shelf and Reports Q2 Earnings - AInvest
Coya Therapeutics Files $75 Million Mixed Shelf - MarketScreener
Coya Therapeutics Highlights Q2 2025 Financial Results - TipRanks
Coya Therapeutics, Inc. SEC 10-Q Report - TradingView
Sector ETF performance correlation with Coya Therapeutics Inc.Trading Watchlist with Real Time Filters - Newser
Finanzdaten der Coya Therapeutics Inc-Aktie (COYA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Coya Therapeutics Inc-Aktie (COYA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| SNYDER DAVID S | Chief Financial Officer |
Nov 14 '24 |
Buy |
7.19 |
1,800 |
12,934 |
8,800 |
| Swaminathan Arun | Chief Executive Officer |
Nov 13 '24 |
Buy |
7.36 |
5,000 |
36,797 |
10,000 |
| Grossman Fred | Chief Medical Officer |
Nov 11 '24 |
Buy |
7.37 |
2,710 |
19,973 |
2,710 |
| Swaminathan Arun | Chief Executive Officer |
Nov 11 '24 |
Buy |
7.34 |
5,000 |
36,689 |
5,000 |
0.88%
7.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):